Abstract
The mechanisms involved in the tumor-stroma interaction during carcinoma progression are an area of intensive investigation. Cancer cells produce a range of growth factors and proteolytic enzymes that modify their stromal environment. These factors disrupt normal tissue homeostasis and act in a paracrine manner to induce angiogenesis and inflammation, as well as activation of surrounding stromal cell types such as fibroblasts, smooth-muscle cells and adipocytes, leading to the secretion of additional growth factors and proteases. Recent studies reveal that fibroblasts have more profound influence on the development and progression of carcinoma than was previously appreciated. These cancer-associated fibroblasts (CAFs) are a heterogeneous fibroblast population with different life-span which are activated and recruited during carcinoma progression. One of the more provocative implications is that genetically altered or/and senescence fibroblasts can induce epithelial cells to form carcinomas. In this article, we will review some evidences that CAFs produce a number of paracrine factors that affect several aspects of pleural and urothelial cancer progression. Moreover, we discuss how this new perspectives on the role of CAFs during cancer initiation and progression can have important implications to cancer therapy.
Keywords: CAFs, tumor stroma, myofibroblasts, pleural cancer, urothelial cancer
Current Signal Transduction Therapy
Title: Emerging Role of Stromal Fibroblasts in Epithelial Cancer
Volume: 1 Issue: 3
Author(s): Maria Rita Rippo, Antonio Procopio and Alfonso Catalano
Affiliation:
Keywords: CAFs, tumor stroma, myofibroblasts, pleural cancer, urothelial cancer
Abstract: The mechanisms involved in the tumor-stroma interaction during carcinoma progression are an area of intensive investigation. Cancer cells produce a range of growth factors and proteolytic enzymes that modify their stromal environment. These factors disrupt normal tissue homeostasis and act in a paracrine manner to induce angiogenesis and inflammation, as well as activation of surrounding stromal cell types such as fibroblasts, smooth-muscle cells and adipocytes, leading to the secretion of additional growth factors and proteases. Recent studies reveal that fibroblasts have more profound influence on the development and progression of carcinoma than was previously appreciated. These cancer-associated fibroblasts (CAFs) are a heterogeneous fibroblast population with different life-span which are activated and recruited during carcinoma progression. One of the more provocative implications is that genetically altered or/and senescence fibroblasts can induce epithelial cells to form carcinomas. In this article, we will review some evidences that CAFs produce a number of paracrine factors that affect several aspects of pleural and urothelial cancer progression. Moreover, we discuss how this new perspectives on the role of CAFs during cancer initiation and progression can have important implications to cancer therapy.
Export Options
About this article
Cite this article as:
Rita Rippo Maria, Procopio Antonio and Catalano Alfonso, Emerging Role of Stromal Fibroblasts in Epithelial Cancer, Current Signal Transduction Therapy 2006; 1 (3) . https://dx.doi.org/10.2174/157436206778226969
DOI https://dx.doi.org/10.2174/157436206778226969 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
STAT3 Activation in Circulating Monocytes Contributes to Neovascular Age-Related Macular Degeneration
Current Molecular Medicine Topical Lipid Based Drug Delivery Systems for Skin Diseases: A Review
Current Drug Therapy Using an Ancient Tool for Igniting and Propagating Immune Tolerance: IDO as an Inducer and Amplifier of Regulatory T Cell Functions
Current Medicinal Chemistry Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines
Current Cancer Drug Targets Animal Models for Growth Hormone Gene Therapy
Current Gene Therapy Progesterone Receptor Membrane Component 1 and its Accomplice: Emerging Therapeutic Targets in Lung Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Role of miRNA in Metastatic Cascade of Triple-Negative Breast Cancer
Current Cancer Drug Targets Lactoferrin: A Biologically Active Molecule for Bone Regeneration
Current Medicinal Chemistry Clinical Importance of Assessment of Type 2 Diabetes Mellitus with Visceral Obesity. A Japanese Perspective
Current Diabetes Reviews Matrixmetalloproteinase Inhibitors: Promising Therapeutic Targets Against Cancer
Current Pharmaceutical Design Sympathetic Signaling in Angiogenesis: Implications for Cancer Progression
Current Cancer Therapy Reviews Epigenetic Regulation of EMT: The Snail Story
Current Pharmaceutical Design Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy HPV Infections: Basis of Neoplastic Transformation and Related Molecular Tests
Current Pharmaceutical Design p73 as a Pharmaceutical Target for Cancer Therapy
Current Pharmaceutical Design Functionalized magnetic nanoparticles for biomedical applications
Current Pharmaceutical Design Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Modulation of Microglial Innate Immunity in Alzheimers Disease by Activation of Peroxisome Proliferator-activated Receptor Gamma
Current Medicinal Chemistry Application of Pharmacogenomics to Dietary Cancer Chemoprevention
Current Pharmacogenomics Oxidative Stress, Redox Signaling and Cancer Chemoresistance: Putting Together the Pieces of the Puzzle
Current Medicinal Chemistry